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Lung Cancer with Localized Ground-Glass Attenuation
Represents Early-Stage Adenocarcinoma in Nonsmokers
Nobuhiko Seki, MD,* Shigeki Sawada, MD,† Masao Nakata, MD,‡ Takeshi Inoue, MD,§
Rieko Nishimura, MD, Yoshihiko Segawa, MD,¶ Reishi Shibakuki, MD,# and Kenji Eguchi, MD*
Background: Studies of lung cancer showing localized ground-
glass attenuation (GGA) on thin-section computed tomography
(TSCT) have been limited to resected stage IA adenocarcinomas.
This study aimed to clarify the features of localized GGA cancer as
a distinct clinicoradiological entity through a survey of lung cancers
of all types.
Methods: From 2000 through 2002, 492 patients with newly diag-
nosed stage I–IV lung cancer underwent TSCT at a single institu-
tion. The tumors were semiquantitatively classified into four groups
on the basis of GGA area as a percentage of the whole tumor shadow
(GGA ratio) on TSCT images: 100%, 99–50%, 49–1%, and 0%.
The relationship between clinicopathological data and the GGA
ratio, predictors of the presence of GGA, survival data, and prog-
nostic factors were evaluated retrospectively.
Results: All localized GGA cancers were adenocarcinomas (p 
0.05). A GGA component was not found in patients with advanced
cancer (p  0.05). GGA cancer was related to nonsmoking status
(Odds ratio 6.17, p  0.05). A threshold tumor size of 30 mm in
GGA cancer (hazard ratio, 2.86; p  0.01) and the GGA ratio
(hazard ratio, 4.17; p  0.01) were independent prognostic factors.
Survival rates were higher in patients with a GGA ratio 50% and
stage IB lung cancer than in patients with a GGA ratio 50% and
stage IA lung cancer.
Conclusion: Localized GGA cancer, with presurgical prognostic
factors of tumor size and GGA ratio, represents early-stage lung
adenocarcinoma in nonsmokers.
Key Words: Thin-section computed tomography, Localized ground-
glass attenuation, Lung cancer, Adenocarcinoma, Bronchioloalveo-
lar carcinoma, Nonsmoker.
(J Thorac Oncol. 2008;3: 483–490)
Localized ground-glass attenuation (GGA) has become amajor concern as lung cancer screening with low-dose
helical computed tomography (CT) becomes more widely
available.1–3 On thin-section CT (TSCT), GGA is a hazy,
increased attenuation of lung tissue with preservation of
vascular margins.4 Although GGA is usually a nonspecific
finding associated with several pulmonary disorders, some
recent studies suggest that localized, well-circumscribed ar-
eas of GGA often represent malignant tumors.2,5–9 Other
recent reports have shown that such tumors are often adeno-
carcinomas, in particular, bronchioloalveolar carcinoma
(BAC) or adenocarcinoma with a BAC component,3,10–16 at
an earlier and potentially more curable stage.17–22 Therefore,
lung cancer showing a GGA ratio of 100–1% on TSCT
(localized GGA cancer) might be recognized as a clinicora-
diological entity distinct from conventional lung cancer
showing homogeneous consolidation of a nodule or mass
(non-GGA cancer).
However, most studies of localized GGA have included
only surgically resected adenocarcinomas no larger than 30
mm in diameter.3,5–8,10–22 Such studies cannot document all
features of localized GGA cancer. Therefore, to establish
localized GGA cancer as a distinct clinicoradiological entity,
studies should include lung cancers of all types, including
adenocarcinomas 30 mm or greater in diameter and stage
II–IV carcinomas. Moreover, localized GGA cancers should
be compared with non-GGA cancers by means of demo-
graphic and survival data.
Findings to date raise several questions. (1) Would all
localized GGA cancers be adenocarcinomas if all types of
lung cancer were evaluated? (2) Is a GGA component present
in patients with advanced (inoperable clinical stage IIIB or
IV) lung cancer? (3) Is GGA cancer related to age, sex, or
smoking history? (4) Is the tumor size of GGA cancer, in
addition to the GGA ratio, an independent prognostic factor?
(5) If so, is the prognosis better for patients with a higher
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GGA ratio but larger tumors or for patients with smaller
tumors and a lower GGA ratio?
This study aimed to clarify the features of localized GGA
cancer as a distinct clinicoradiological entity by addressing these
questions through a survey of lung cancers of all types.
PATIENTS AND METHODS
Patients
We reviewed the records of 529 consecutive patients
with primary lung cancer newly diagnosed at the National
Hospital Organization Shikoku Cancer Center from June
2000 through May 2002. Although TSCT was performed
routinely, scans were not available for 37 patients; therefore,
492 patients were evaluated. The tumor stage was established
with the International Staging System.23 Tumors were stage I
in 237 patients, and stage II–IV in 255 patients. In cases of
synchronous lung cancer, the most advanced tumor was consid-
ered the index tumor.24–27 Our institutional review board does
not require its approval or patient informed consent for retro-
spective studies of case records and CT images.
Determination of GGA Ratio on TSCT Images
Patients underwent TSCT without contrast enhance-
ment using a Somatom Plus 4 scanner (Siemens Medical
Systems, Erlangen, Germany; 120 kVp, 250 mA, 1.0-second
scanning time, 2.0-mm-thick sections). Localized GGA was
defined as a focal area of GGA with smooth and distinct
borders on TSCT images with a fixed lung window setting (a
level of 700 and a width of 1500 Hounsfield units). The
GGA ratio was calculated semiquantitatively as [(DGGA D)/
DGGA]  100, where DGGA and D are the greatest diameters of
the entire tumor and the non-GGA component, respectively.21
Tumors were divided on the basis of GGA ratio into four
FIGURE 1. Transverse thin-section
computed tomography images of lung
adenocarcinoma. Tumors were classi-
fied into four groups according to
semiquantitatively calculated GGA ra-
tios. (A) 100% GGA ratio tumor, (B)
99–50% GGA ratio tumor, (C) 49–1%
GGA ratio tumor, and (D) 0% GGA
ratio tumor.
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groups: 100%, 99–50%, 49–1%, and 0% (Figure 1). Tumors
were assigned to groups according to the consensus judgment
of two investigators (N.S. and K.E.), who were blinded to
clinical information.
Determination of Histologic Classification
Pathologic specimens were stained with hematoxylin
and eosin. The histologic classification was established with
World Health Organization criteria28 by a lung pathologist
(R.N.), who reviewed all specimens for this study. The histo-
logic diagnosis was adenocarcinoma in 308 patients, squa-
mous cell carcinoma in 108 patients, small cell carcinoma in
51 patients, large cell carcinoma in 12 patients, and other
non-small cell carcinoma in 13 patients. Adenocarcinoma
was subclassified as BAC or adenocarcinoma with or without
a BAC component.
Tumor Resection and Follow-up
The patient flow of this study is summarized in Figure
2. Of the 237 patients with clinical stage I lung cancers, 225
underwent surgery, two received chemoradiotherapy, six re-
ceived radiotherapy, and four received best supportive care.
Patients undergoing resection of stage I lung cancer received
neither radiotherapy nor chemotherapy before or after sur-
gery. From June 2000 through December 2001, thoracoscopic
wedge resection was performed for tumors 10 mm or less in
diameter with a GGA ratio of 100%.29 Standard resection was
performed for all other tumors.
Although this is not a prospective study and the fol-
low-up procedure was, therefore, not strictly regimented,
follow-up care by the same two surgeons (S.S. and M.N.) at
a single institution allowed patients to be followed up with
standardized examinations. Physical examination, chest roent-
genography, and tumor markers as appropriate were per-
formed every month within the first year and at 3- to 6-month
intervals thereafter. Chest CT, abdominal ultrasonography,
brain CT or magnetic resonance, and bone scintigraphy were
performed every 6 months through the third year and annu-
ally thereafter. If a relapse was detected with these imaging
techniques, the patient underwent further examinations as
required. All patients were followed up, for a median duration
of 36 months (range, 1–78 months).
Statistical Analysis
To compare data between groups, one-way analysis
of variance or the Kruskal-Wallis test was used, followed
by Scheffe’s test. Spearman’s rank correlation coefficients
were analyzed for relationships between groups. Multivar-
iate logistic regression analysis was performed for predic-
tors of GGA. Relapse-free survival curves were con-
structed with the Kaplan-Meier method, followed by the
log-rank test. Multivariate Cox proportional hazards model
analysis was performed for prognostic factors. All calcu-
lations were performed with Stat View 5.0J software (SAS
Institute Inc., Cary, NC). p values 0.05 indicated statis-
tical significance.
RESULTS
Relationship Between Clinicopathological Data
and GGA Ratio
Patient’s clinicopathological data according to GGA
ratio are summarized in Table 1. Age was lowest in the 100%
Patients with stage I-IV lung cancer
(n = 529)
Thin-section CT Available (n =492) Not available (n =37)
GGA ratio 100% (n = 38)
c-stage I (n =237)
c-stage II-IV
n = 38 n = 27 n = 50 n = 122
n = 255
c-stage I 
surgery (n = 225)
non-surgery
n = 38 n = 27 n = 49
n =   1
n = 111
n =   11
n =   32
n = 223
c-stage II-IV 
surgery
non-surgery
99-50% (n = 27) 49-1% (n = 50) 0% (n = 377)
FIGURE 2. Patient flow. CT, computed tomography.
TABLE 1. Patients’ Clinicopathological Characteristics According to GGA Ratio
GGA Ratio (%)
pa
100
(n  38)
99–50
(n  27)
49–1
(n  50)
0
(n  377)
Age (yr), mean  SD 61  10 66  8 66  9 66  11 0.05b
Gender, % of female 58 48 68 23 0.05c
Smoking, % of nonsmoker 63 56 70 18 0.05c
Tumor size (mm), mean  SD 11  5 25  10 24  11 39  19 0.05d
Clinical stage, % of stage I 100 100 100 32 0.05c
Histology, % of adenocarcinoma 100 100 100 51 0.05c
a One-way analysis of variance or Kruskal–Wallis test, followed by Scheffe’s test.
b Significant difference between GGA 100% and each of the other three groups, but not between each two of the other
three groups.
c Significant difference between GGA 0% and each of the other three groups, but not between each two of the other three groups.
d Significant difference between GGA 100% and each of the other three groups, and also between GGA 0% and each of the
other three groups.
SD, standard deviation.
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GGA ratio group (p  0.05) but did not differ significantly
between the other three groups. The percentages of female
patients and of nonsmokers were significantly higher (p 
0.05, p  0.05, respectively) in groups with GGA ratios of
100%, 99–50%, or 49–1% than in the group with a GGA
ratio of 0% but did not differ significantly among the former
three patient groups. Similarly, the frequencies of clinical
stage I and of adenocarcinoma were significantly higher (p 
0.05, p  0.05, respectively) in these three groups than in the
0% GGA ratio group. Neither clinical stage II–IV disease nor
cancers other than adenocarcinoma were found in these three
groups. Tumors were smallest in the 100% GGA ratio group
and largest in the 0% GGA ratio group (p  0.05).
Predictors of GGA
Multivariate logistic regression analysis demonstrated
that only smoking history (p  0.01) was significantly asso-
ciated with GGA (Table 2). The likelihood of GGA in
nonsmokers was 6.17 times that in smokers.
Relationship Between Histopathological Data
and GGA Ratio
Pathologic characteristics of resected clinical stage I
lung cancer according to GGA ratio are summarized in Table
3. The rate of clinical stage IA disease was highest in the
100% GGA ratio group (p  0.05) and did not differ
significantly between the other three groups. Clinical stage IB
disease was not observed in the 100% GGA ratio group. The
rate of pathologic stage IA disease was highest in the 100%
GGA ratio group and lowest in the 0% GGA ratio group (p
0.05). Neither pathologic stage IB nor II-IIIA disease was
found in the 100% GGA ratio group, whereas neither patho-
logic stage IIIB nor IV disease was observed in any of the
four groups. Furthermore, pathologic stage was negatively
correlated with the GGA ratio (r  0.33, p  0.001).
Similarly, the rate of BAC was highest in the 100% GGA
ratio group and lowest in the 0% GGA ratio group (p 0.05).
Adenocarcinoma without a BAC component was not ob-
served in the 100% GGA ratio group, whereas cancers other
than adenocarcinoma were found only in the 0% GGA ratio
group. Moreover, histologic subtype was negatively corre-
lated with the GGA ratio (r  0.35, p  0.001).
Presurgical Prognostic Factors
After independent variables were selected from among
presurgical data, multivariate analysis with the Cox proportional
hazards model revealed that clinical stage IA or IB disease (p
0.01) and the GGA ratio (p  0.01) were independent risk
factors for relapse-free survival in 225 patients with clinical
stage I lung cancers (Table 4). The likelihood of relapse in
patients with clinical stage IB disease was 2.86 times that in
patients with clinical stage IA disease. Furthermore, the risk of
relapse increased 4.17-fold with the stepwise decrease of the
GGA ratio from 100%, through 99–50% and 49–1%, to 0%.
When a tumor size of 20 mm was used instead of 30
mm as a cut-off value, the GGA ratio was the only significant
independent risk factor.
Combined Effects of GGA Ratio and Tumor Size
Relapse-free survival rates, stratified by both the GGA
ratio and clinical stage, are shown in Figure 3. The 5-year
TABLE 2. Predictor for the Presence of GGA
Variables (Likely
vs. Unlikely)
Odds
Ratioa
95%
Confidence
Interval p
Age (yr), 65 vs. 65 1.20 0.75–1.90 0.45
Gender, female vs. male 1.41 0.73–2.74 0.31
Smoking, nonsmoker vs. smoker 6.17 3.18–11.97 0.01
a Likely/unlikely.
TABLE 3. Pathological Characteristics of Resected Clinical Stage I Lung Cancer
GGA Ratio (%)
pa
100
(n  38)
99–50
(n  27)
49–1
(n  49)
0
(n  111)
Clinical stage
IA 38 17 35 81 0.05b
IB 0 10 14 30
Pathological stage
IA 38 17 35 61 0.05c
IB 0 9 12 19
II–IIIA 0 1 2 31
Histological subtype
Bronchioloalveolar carcinoma (BAC) 30 11 10 11 0.05c
Adenocarcinoma with BAC component 8 13 31 7
Adenocarcinoma without BAC component 0 3 8 58
Squamous/large/small cell carcinoma 0 0 0 28/2/5
a Kruskal–Wallis test, followed by Scheffe’s test.
b Significant difference between GGA 100% and each of the other three groups, but not between each two of the other three
groups.
c Significant difference between GGA 100% and each of the other three groups, and also between GGA 0% and each of the
other three groups.
Seki et al. Journal of Thoracic Oncology • Volume 3, Number 5, May 2008
Copyright © 2008 by the International Association for the Study of Lung Cancer486
relapse-free survival rate, especially that of patients with
stage IB disease, was highest (100%) when the GGA ratio
was 50% (n  10), whereas that of patients with stage IA
disease was 95.5% when the GGA ratio was 49–1% (n 35)
and was 67.7% when the GGA ratio was 0% (n 81). Relapse
occurred through local recurrence or distant metastasis.
DISCUSSION
The present study has demonstrated that clinical fea-
tures differ between localized GGA cancer and non-GGA
cancer in the following ways: (1) The histologic type of
localized GGA cancer is limited to adenocarcinoma. (2)
Localized GGA cancer is not present in patients with ad-
vanced lung cancer. (3) Localized GGA cancer is related to
nonsmoking status. (4) The size of localized GGA cancer
(30 mm or 30 mm) is, in addition to the GGA ratio, an
independent prognostic factor, as it is for non-GGA cancer.
(5) Patients with a GGA ratio50% and stage IB lung cancer
have a better prognosis than do patients with a GGA ratio
50% and stage IA lung cancer. To our knowledge, this is
the first study to clarify the features of localized GGA cancer
as a distinct clinicoradiological entity.
In the present study, all localized GGA cancers were
adenocarcinomas, although lung cancers of all types were
examined. To date, most studies of localized GGA cancer
have cited four earlier studies as evidence that localized GGA
on TSCT images indicates focal BAC, mostly representing a
growth pattern of tumor cells replacing alveolar lining
cells.10–13 However, the CT criteria for localized GGA pro-
posed by Kuhlman et al. differ from those used in most recent
studies,2,5–9 leading to considerable overlap with the CT
criteria for large-cell carcinoma.10 Similarly, Zwirewich et al.
have investigated 85 resected malignant nodules on the basis
of CT criteria for localized GGA that differ from ours.11
Kushihashi et al. have correlated only four bronchioloalveo-
lar adenomas, but not BAC, with TSCT images from among
668 lung cancers but did not mention the presence of GGA
among other cancers.12 Similarly, Jang et al. have reviewed
TSCT images of only four patients with focal BAC.13 More-
over, Sakai et al. have reported that no localized GGA was
observed on TSCT images in 30 cases of surgically resected
peripheral squamous cell carcinomas, including eight carci-
nomas with alveolar lining tumor permeation and fibrous
thickening of alveolar septa,30 which might pathologically
mimic adenocarcinoma with a BAC component and corre-
sponds to the diffuse desmoplastic type of squamous cell
carcinoma proposed by Tokuda et al.31 Therefore, ours is the
first study providing evidence that localized GGA cancers are
adenocarcinomas, especially BAC or adenocarcinoma with a
BAC component.
Furthermore, all localized GGA cancers in our study
were clinical stage I and never progressed to pathologic stage
IIIB or IV, although all types of lung cancers were evaluated.
To date, most studies of localized GGA cancer have involved
only resected clinical stage IA adenocarcinomas, which do
not exceed pathologic stage IIIA.17–20 However, we wonder
whether localized GGA cancer of any size is present in
patients with inoperable clinical stage IIIB or IV disease. This
question is difficult to answer on the basis of previous reports,
considering that TSCT is not routinely performed for clinical
stage IIIB or IV primary lung cancers. In our study 176 of 195
patients with clinical stage IIIB or IV primary lung cancer
underwent TSCT, but no localized GGA cancer was ob-
served. An important question is why localized GGA cancer
was not found in patients with clinical stage IIIB or IV
disease, although metastasis to mediastinal lymph nodes had
occurred before surgery in some cases and postoperative
relapse or distant metastasis was possible in other cases.
Although the reason localized GGA cancer was not found
remains unclear, some clues have been obtained. Saito et al.
have reported that, during their long-term follow-up of eight
localized GGA cancers, vascular involvement increased in all
cases, areas of high attenuation (non-GGA component) ap-
peared within the areas of GGA before an increase in the size
of the entire tumor in seven cases, and a marked increase in
the size of the non-GGA component was observed in two
TABLE 4. Presurgical Prognostic Factors
Variables (Unfavorable
vs. Favorable)
Hazard
Ratioa
95%
Confidence
Interval p
Age (yr), 65 vs. 65 1.33 0.63–2.86 0.46
Gender, male vs. female 1.37 0.57–3.33 0.48
Smoking, smoker vs. nonsmoker 1.12 0.74–1.72 0.58
Clinical stage, IB vs. IA 2.86 1.35–5.88 0.01
GGA ratio (%), 0 vs. 1–49 vs.
50–99 vs. 100
4.17 1.67–11.11 0.01
a Unfavorable/favorable.
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0
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40
60
80
100
(e)
(d)
(f)
GGA 0%: (d) stage IA (n = 81) vs. (f) stage IB (n = 30), P = 0.019 
GGA 49-1%: (c) stage IA (n = 35) vs. (e) stage IB (n = 14), P = 0.047
(c)
(a), (b)
GGA 50%: (a) stage IA (n = 55), (b) stage IB (n = 10)
FIGURE 3. Relapse-free survival curves stratified by both
GGA ratio and clinical stage. The 5-year relapse-free survival
rate of patients with stage IA disease (n  55) or stage IB
disease (n  10) was highest (100%) when the GGA ratio
was 50%. When the GGA ratio was 49–1%, the 5-year
relapse-free survival rate of patients with stage IA disease
(n  35; 95.5%) was significantly greater than that of pa-
tients with stage IB disease (n  14; 61.9%, p  0.047).
Similarly, when the GGA ratio was 0%, the 5-year relapse-
free survival rate of patients with stage IA disease (n  81;
67.7%) was significantly greater than that of patients with
stage IB disease (n  30; 54.6%, p  0.019).
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cases.32 Therefore, our proposed explanation is that the pro-
gression of GGA cancer might be followed by both increased
metastatic potential and architectural distortion of the GGA
component.
That localized GGA cancer is a distinct clinicoradio-
logical entity is supported by differences in time-independent
factors (gender, smoking history, and histologic type; Table
1) between the 0% GGA ratio group and the groups with
GGA ratios of 100%, 99–50%, and 49–1% and by the lack of
differences among these latter three groups. Furthermore,
multivariate analysis showed that localized GGA cancer was
related to nonsmoking status but not to the female sex. To
date, anecdotal evidence has suggested that localized GGA
cancer tends to be detected in female nonsmokers. If local-
ized GGA cancer represents, in particular, BAC or adenocar-
cinoma with a BAC component, the percentage of nonsmok-
ers correlates with the percentage of female subjects, as in
epidemiologic studies of BAC.33–38 Thus, Barkley et al. have
documented without multivariate analysis that patients with
BAC are more likely to be woman and nonsmokers.39 How-
ever, through multivariate analysis of 1635 patients, Grover
et al. have demonstrated that nonsmoking status, but not the
female sex, predicts BAC.34 Moreover, Kosaka et al. have
shown with univariate analysis that epidermal growth factor
receptor mutations, which are common in BAC and adeno-
carcinoma with a BAC component, are more frequent in
woman and in nonsmokers, but Kosaka et al. have also shown
with multivariate analysis that epidermal growth factor re-
ceptor mutations are independently associated with nonsmok-
ing status but not with the female sex.40
In the present study, some adenocarcinomas without
BAC component showed GGA on TSCT (Table 3). The
histologic subtype of all these adenocarcinomas was papillary
adenocarcinoma. Regarding the specific findings of these
tumors, the area of air space in pathologic specimens was
large because of a relative absence of thick papillary struc-
tures, compact cellular growth pattern, and acinar filling.
Therefore, considering that the presence of localized GGA is
associated with a high percentage of air-containing areas in
the tumor, it seems reasonable that some papillary adenocar-
cinomas with such specific findings showed localized GGA
on TSCT and that the other subtypes of lung carcinoma
presenting a solid and nesting growth pattern with dense
fibrous tissue showed a GGA ratio of 0% on TSCT. In fact,
Aoki et al. have demonstrated that 3.2% of adenocarcinomas
without a BAC component showed a GGA ratio of 10% to
50% on TSCT.21 Furthermore, Henschke et al. have also
demonstrated that adenocarcinomas are the only lung carci-
nomas that show GGA findings.2 However, more important is
the fact that the prognosis of localized GGA cancers, even if
adenocarcinomas without a BAC component are included, is
better than that of non-GGA cancers. This more-favorable
prognosis is the reason localized GGA cancer is an important
clinicoradiological entity.
Our study found that size is an important factor in
localized GGA cancer as well. That is, for patients with
clinical stage I disease, both tumor size and the GGA ratio
might be independent prognostic factors when a threshold
value of 30 mm is used. In previous studies, a tumor diameter
of less than 30 mm was found not to be an independent
prognostic factor for localized GGA cancer.17–22 Therefore, our
finding that a tumor size of 30 mm has prognostic value, despite
our other finding that a tumor size of 20 mm has no prognostic
significance, strengthens the reliability of our results.
The results of our study of the combined effects of the
GGA ratio and tumor size in patients with clinical stage I
disease and localized GGA cancer have several interesting
implications. First, in patients who had tumors with a GGA
ratio 50%, the 5-year relapse-free rate was 100% for both
clinical stage IA and IB disease. Therefore, the clinical stage
of patients who have tumors with a GGA ratio 50% might
need to be decreased below the conventional clinical stage of
IA, regardless of tumor size. Second, patients with a GGA
ratio 50% and stage IB lung cancer have a better prognosis
than do patients with a GGA ratio 50% and stage IA lung
cancer. In two recently published series, the frequency of
multicentric adenocarcinoma was 8.4 to 21.5%,41,42 although
the prevalence of multicentric lung cancer was 0.8 to 3.0% in
most other series.24–27 Furthermore, the frequency of syn-
chronous lung cancer with stage IB being the highest stage
was 18 to 38% among all synchronous lung cancers.27,41 So far,
the most common surgical procedure for such cases is a com-
bination of lobectomy for the most-advanced tumors and limited
resection for less-advanced tumors.26,27,41 Therefore, our results
might be useful for selecting treatment for patients with clinical
stage IA or IB disease and synchronous GGA cancer.
Our study had several limitations. A first limitation is
that although analysis with CT software for calculating the
GGA ratio 2- or 3-dimensionally might have been more
accurate, it was not available for our study. However, in most
previous studies, semiquantitative methods have been em-
ployed to calculate the GGA ratio, resulting in sufficient
clinical benefit.17–22 A second limitation is that our study is a
retrospective cohort study of patients from a single cancer-
center hospital, which may have led to a selection bias of
patients with localized GGA cancers. If larger prospective
cohort studies are performed, localized GGA cancer other
than early-stage adenocarcinoma might be detected. There-
fore, the possibility of such bias might limit the strength of
our conclusions. In fact, advanced adenocarcinomas, such as
mucinous adenocarcinomas, can manifest as solitary or mul-
tifocal GGA. Moreover, lung cancers of other histologic
types can manifest as localized GGA due to peritumoral
hemorrhage regardless of stage. However, previous reports
regarding mucinous and nonmucinous BAC have indicated
that advanced mucinous adenocarcinomas very rarely show
solitary GGA and that most show the combination of multi-
focal GGA and non-GGA lesions.33,35–39 In addition, Li et al.
have demonstrated that persistent localized GGA is most
frequently attributed to BAC and that short-term follow-up
imaging can be helpful for differentiating benign from ma-
lignant GGA lesions, because all benign GGA lesions in their
series, including those with peritumoral hemorrhage, had
partially or completely resolved within 3 months.43 A third
limitation is that regarding the strict diagnosis of adenocar-
cinoma with multiple localized GGA, the distinction between
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multicentric origins (field cancerization) and metastasis re-
mains poorly defined. Therefore, in our study, whether ade-
nocarcinoma manifested as multiple localized GGA can be
considered stage I lung cancer was decided on the basis of
clinical and pathologic criteria.24–27 In the future, a better
understanding of the molecular nature of such cancers may
open new avenues for the study of patients with multiple
localized GGA. A fourth limitation of the present study is that
patients with metastatic lung tumors were not evaluated. In
the setting of neoplastic diseases other than lung cancer, local-
ized GGA on TSCT is considered to reflect lung metastasis from
adenocarcinoma of the gastrointestinal tract or pulmonary in-
volvement of lymphoma or malignant melanoma.44,45 However,
Steele has shown that only 3% of 887 asymptomatic patients
with solitary pulmonary nodules had metastases and that some
neoplastic diseases, including melanoma and carcinoma of the
colon, were more likely to produce solitary metastases.46 Con-
sidering that even solitary metastatic lung tumors present a
varied appearance on TSCT, localized GGA cancer that is
attributed to metastasis is expected to be distinctly uncom-
mon. Therefore, localized GGA cancer is not always primary
lung adenocarcinoma; however, we still insist on the strong
association of localized GGA cancer with lung adenocarci-
noma in terms of its high prevalence among neoplastic
diseases showing localized GGA on TSCT.44
CONCLUSION
In conclusion, localized GGA cancer, for which tumor
size and GGA ratio are presurgical prognostic factors, repre-
sents early-stage lung adenocarcinoma in nonsmokers. Fur-
ther studies are required to validate our results and to better
clarify the features of localized GGA cancer as a distinct
clinicoradiological entity.
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